MPL and thrombocytosis disease: And ruxolitinib ameliorated the thrombocytosis in CALR mutant mice and attenuated the increase in number of BM megakaryocytes and HSCs, revealing a vital role for MPL and STAT5 activation in CALR mutation-induced MPN (141).